Filtered By:
Condition: Hypertension
Drug: Coumadin
Education: Study
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 156 results found since Jan 2013.
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of medicare part d beneficiaries.
CONCLUSIONS: Warfarin use rates vary by patient characteristics and region, with higher rates among residents of the Midwest and among patients seen by cardiologists and PCPs. Preventing stroke-related disability in AF requires implementation of evidence-based initiatives to increase warfarin use.
PMID: 23324508 [PubMed - in process]
Source: The Annals of Pharmacotherapy - January 1, 2013 Category: Drugs & Pharmacology Authors: Raji MA, Lowery M, Lin YL, Kuo YF, Baillargeon J, Goodwin JS Tags: Ann Pharmacother Source Type: research
Upper limb arterial thromboembolism: A systematic review on incidence, risk factors, and prognosis including a meta‐analysis of risk‐modifying drugs
ConclusionsAge, female sex, AF, hypertension, diabetes, myocardial infarction, heart failure and stroke are most common risk factors for thromboembolectomy of the upper limb. The availability of NOAC holds promise in reducing the risk of systemic thromboembolism, but specific data are still limited.© 2013 International Society on Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis - February 25, 2013 Category: Hematology Authors: L V. Andersen, G Y.H. Lip, J S. Lindholt, L Frost Tags: Original Article ‐ Cardiovascular Medicine Source Type: research
Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta‐analysis of risk‐modifying drugs
ConclusionsAge, female sex, AF, hypertension, diabetes, myocardial infarction, heart failure and stroke are most common risk factors for thromboembolectomy of the upper limb. The availability of new OACs holds promise for reducing the risk of systemic thromboembolism, but specific data are still limited.
Source: Journal of Thrombosis and Haemostasis - May 15, 2013 Category: Hematology Authors: L. V. Andersen, G. Y. H. Lip, J. S. Lindholt, L. Frost Tags: Original Article Source Type: research
Missed Opportunities for Appropriate Anticoagulation Among Emergency Department Patients With Uncomplicated Atrial Fibrillation or Flutter
Conclusion: In this cohort of ED patients with uncomplicated atrial fibrillation or flutter who were discharged without cardiology involvement, many were not appropriately anticoagulated before ED arrival, and more than half of such patients did not appear to have corrective measures initiated by the emergency physician. This may represent a potential opportunity to improve patient care and outcomes.
Source: Annals of Emergency Medicine - May 28, 2013 Category: Emergency Medicine Authors: Frank X. Scheuermeyer, Grant Innes, Reza Pourvali, Chris Dewitt, Eric Grafstein, Claire Heslop, Jan MacPhee, John Ward, Brett Heilbron, Lorraine McGrath, Jim Christenson Tags: Cardiology Source Type: research
Predictors of Anticoagulant Treatment in Patients With Nonvalvular Atrial Fibrillation: Results From Atrial Fibrillation in Turkey: Epidemiologic Registry
In this study, we demonstrated that stroke history, persistent/permanent AF, hypertension, DM, and left atrial diameter were positive predictors, whereas advanced age and heart failure were negative predictors of oral anticoagulant use in patients with nonvalvular AF.
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2015 Category: Hematology Authors: Kaya, H., Ertaş, F., Koroğlu, B., Vatan, B., Cağlıyan, C. E., Gedik, S., Yeter, E., Aydin, M., Akil, M. A., Soydinc, M. S., Ozhan, H., Ulgen, M. S., for the AFTER Investigators Tags: Original Articles Source Type: research
Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA 2 DS 2 -VASc Score (Beyond Sex)
Whether to anticoagulate patients with atrial fibrillation (AF) and 1 stroke risk factor (i.e., CHA2DS2-VASc [congestive heart failure, hypertension, age>75 years, diabetes mellitus, stroke, vascular disease, age 65–75 years, and female sex] score = 1 in men, or 2 in women) is controversial, but many studies report ischemic stroke rates of>1.5% per year, even with 1 stroke risk factor (1). We estimated the net clinical benefit (NCB) of aspirin or warfarin compared with no antithrombotic therapy among such patients on the basis of a nationwide Danish cohort, with incident AF diagnosed between 1998 and 2012 (2). Men w...
Source: Journal of the American College of Cardiology - July 20, 2015 Category: Cardiology Source Type: research
Prevalence of atrial fibrillation in an urban population in India: the Nagpur pilot study
Conclusions
The prevalence of AF was low compared with other regions of the world and stroke prophylaxis was underused. A larger study is needed to confirm these findings. This study demonstrates that larger evaluations would be feasible using the community-based techniques employed here.
Source: Heart Asia - April 17, 2016 Category: Cardiology Authors: Saggu, D. K., Sundar, G., Nair, S. G., Bhargava, V. C., Lalukota, K., Chennapragada, S., Narasimhan, C., Chugh, S. S. Tags: Original research Source Type: research
A prospective study investigating the causes of warfarin under-utilization in Chinese patients
Conclusion Patients with CHA2DS2-VASc scores ≥1 who were admitted with NVAF were under prescribed warfarin, and 138 patients were not treated with either warfarin or other antithrombotic therapies. In conclusion, a more aggressive approach for stroke prevention in NVAF patients is required.
Source: International Journal of Clinical Pharmacy - August 2, 2016 Category: Drugs & Pharmacology Source Type: research
Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China.
CONCLUSION: Oral anticoagulation was significantly underused in NVAF patients in China. Age, sex, concurrent drug usage and disease history were associated factors. Improving warfarin adherence was promising to reduce ischemic stroke risk of NVAF patients.
PMID: 29022745 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - October 13, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
An updated systematic review and meta ‐analysis of early outcomes after left atrial appendage occlusion
ConclusionsThis meta‐analysis concludes that LAAO occlusion is a safe and effective stroke prevention strategy in patients with NVAF.
Source: Journal of Interventional Cardiology - March 1, 2018 Category: Cardiology Authors: Charan Yerasi, Mohamad Lazkani, Prathik Kolluru, Varun Miryala, Jae Kim, Harsha Moole, Abhishek C. Sawant, Michael Morris, Ashish Pershad Tags: ORIGINAL INVESTIGATION Source Type: research
Direct oral anticoagulants in chronic kidney disease: an update
Purpose of review
Direct oral anticoagulants (DOACs) are variably eliminated by the kidneys rendering their use potentially problematic in patients with chronic kidney disease (CKD) or necessitating appropriate dose adjustment.
Recent findings
Both observational and limited randomized trial data for DOACs compared with no treatment or with warfarin for patients with atrial fibrillation on maintenance dialysis were recently published. In a randomized trial in patients on hemodialysis, there was no significant difference in vascular calcification between patients who received rivaroxaban with or without vitamin K2 or vi...
Source: Current Opinion in Nephrology and Hypertension - August 1, 2020 Category: Urology & Nephrology Tags: PHARMACOLOGY AND THERAPEUTICS: Edited by Sankar D. Navaneethan Source Type: research
How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you…
Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China.
I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1
We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004.
Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news
Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry.
CONCLUSIONS: The Fushimi AF Registry provides a unique snapshot of current AF management in an urban community in Japan.
PMID: 23403369 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 8, 2013 Category: Cardiology Authors: Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K, On behalf of the Fushimi AF Registry investigators Tags: J Cardiol Source Type: research
Imaging the aortic arch to improve diagnostic and prognostic accuracy in transient ischemic attack patients
This study raises a final relevant question: since the prognosis of TIA patients worsens in proportion to the severity of AAA, what therapeutic options are available for these patients? The clinical guidelines recommend risk factor modification and therapy with statins (Class IIa, level of evidence C), an approach consistent with treatment of any patient affected by atherosclerosis. Treatment with coumadin or anti-platelet agents can be considered in patients with AAA >4 mm, i.e. severe AAA, but it remains very controversial because of a potential risk of thrombo-embolism (Class IIb, level of evidence C) . Finally, surgi...
Source: Atherosclerosis - November 25, 2013 Category: Cardiology Authors: Paolo Raggi Tags: Invited Commentaries Source Type: research
